BiogenBIIBEarnings & Financial Report
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
BIIB Q4 2025 Key Financial Metrics
营收
$2.3B
毛利润
$1.8B
营业利润
N/A
净利润
$-48.9M
毛利率
78.3%
营业利润率
N/A
净利率
-2.1%
同比增长
-7.1%
EPS
$-0.35
资金流向
Biogen Q4 2025 Financial Summary
Biogen reported revenue of $2.3B for Q4 2025, with a net profit of $-48.9M (-2.1% margin). Cost of goods sold was $495.5M, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.3B |
|---|---|
| Net Profit | $-48.9M |
| Gross Margin | 78.3% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Biogen Annual Revenue by Year
Biogen annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.9B).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.9B |
| 2024 | $9.7B |
| 2023 | $9.8B |
| 2022 | $10.2B |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $2.29B | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B |
| 同比增长 | -7.0% | 0.4% | -2.5% | 2.9% | 6.1% | 7.3% | 2.8% | -7.1% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $26.57B | $26.80B | $28.31B | $28.05B | $28.03B | $28.33B | $29.21B | $29.44B |
| 总负债 | $11.35B | $10.91B | $11.95B | $11.33B | $11.05B | $10.70B | $11.00B | $11.18B |
| 股东权益 | $15.21B | $15.89B | $16.36B | $16.72B | $16.98B | $17.63B | $18.21B | $18.26B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $553.2M | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.27B | $511.9M |
Other Health Care Companies
ABBV
AbbVie
营收
$15.8B
净利润
$186.0M
AMGN
Amgen
营收
$9.9B
净利润
$1.3B
GILD
Gilead Sciences
营收
$7.8B
净利润
$3.1B
INCY
Incyte
营收
$1.5B
净利润
$299.3M
MRNA
Moderna
营收
$1.0B
净利润
$-200.0M
REGN
Regeneron Pharmaceuticals
营收
$3.9B
净利润
$844.6M
VRTX
Vertex Pharmaceuticals
营收
$3.2B
净利润
$1.2B
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
A
Agilent Technologies
营收
$1.9B
净利润
$434.0M
ALGN
Align Technology
营收
$995.7M
净利润
$56.8M